Cancer still represents the second leading cause of death worldwide. Despite the enormous advancements in cancer treatments that can improve the patient’s survival rate, a lot still needs to be achieved to consider cancer a curable disease.
In this fight against cancer, everyone who can accelerate the progress of curative therapies is called to contribute.
Novo Nordisk Pharmatech A/S is honored to contribute to the development and manufacturing of many available anti-cancer monoclonal antibody drugs, supplying Recombinant Insulin as a cell culture ingredient to boost protein productivity in cell culture.
As part of our focus, we want to be part of the future of cancer treatment, supporting innovations in advanced therapies. Collaborating with researchers and biomanufacturer specialists, we aim to accelerate the optimisation of safe cell therapies for patients living with cancer.